Abstract
Dapagliflozin is a new antidiabetic drug from the group of SGLT2 inhibitors - drugs exhibiting favourable efficacy/ safety ratios. It does not increase the risk of hypoglycaemia.
Its effect is independent of insulin and can be administered in combination with oral antidiabetic drugs or with insulin any time over the course of the illness in patients with type 2 diabetes mellitus.